ND Biosciences awarded a grant from The Michael J. Fox Foundation to accelerate the development of its assays
ND Biosciences was founded to develop next-generation therapeutics and diagnostics for neurodegenerative diseases
ND Biosciences was founded to develop next-generation therapeutics and diagnostics for neurodegenerative diseases (NDs).
The therapies developed at ND Biosciences focus on treating both
early and late stages of NDs. This is accomplished by developing
combination therapies that prevent the initiation of pathological
protein aggregation observed in NDs, and that neutralize the activities
of existing protein aggregates.
ND Biosciences has developed integrated proprietary platforms that
enable its transformative drug discovery and preclinical development
programs. These platforms are based on unique capabilities and model
systems that allow ND Biosciences to:
The technologies and innovative tools and discovery platforms employed by ND-BioSciences are based on more than 15 years of innovation and pioneering work that was carried out in the laboratory of its founder, Dr. Hilal A. Lashuel and are well-documented in several high impact peer-reviewed publications.
Fares MB, Jagannath S, Lashuel HA. Reverse engineering Lewy bodies: how far have we come and how far can we go? Nat Rev Neurosci..
Read More
DeGuire SM, Ruggeri SM,Fares MF,Cendrowska U,Dietler G,and Lashuel HA*. Phosphorylation at S13 and/or S16 strongly inhibits the aggregation of mutant Httex1, ...
Read More
Dikiy I, Fauvet B, Jovičić A, Mahul-Mellier A, Desorby C, El-Turk F, Gitler AD, Lashuel HA*, Eliezer D*. Semisynthetic and in vitro phosphorylation of alpha-synuclein...
Read More
Haj-Yahya M and Lashuel HA*. Protein semisynthesis provides access to Tau disease-associated post-translational modifications (PTMs) and paves the way to....
Read More
Reif A, Chiki A, Ricci J, and Lashuel HA*. Generation of native, untagged Huntingtin Exon1 monomers and fibrils using a SUMO fusion strategy....
Read More
Cariulo C, Azzollini L, Verani M, Martufi P, Chiki A, Deguire SM, Cherubini M, Gines S, Marsh LJ, Lavery D, Doherty E, Conforti P, Cattaneo E, Santimone J, ........
Read More
El Turk F, De Genst E, Guilliams T, Fauvet B, Hejjaoui M, Vendruscolo M*, Lashuel HA*, Dobson CM*. “Exploring the role of post-translational modifications in regulating.....
Read More
ND Biosciences awarded a grant from The Michael J. Fox Foundation to accelerate the development of its assays
ND-BioSciences Announces partnership with The Michael J. Fox Foundation for parkinson’s research to make available unique synuclein proteoforms
ND BioSciences, a Swiss-based biotechnology company that was
ND BioSciences, the Swiss biotech co-founded by Prof. Hilal Lashuel, the director of the laboratory of molecular and chemical biology
La start-up qui veut combattre les maladies neurodégénératives par des traitements novateurs
The biotech start-up based at Biopôle is developing innovative technologies for early diagnostics and therapies
The development of disease models that recapitulate the key pathological and clinical features of neurodegenerative diseases
ND BioSciences, the Swiss biotech co-founded by Prof. Hilal Lashuel, the director of the laboratory of molecular and chemical biology
ND BioSciences, a Swiss-based biotechnology company that was
ND BioSciences, a Swiss-based biotechnology company that was